GHK-Cu
What the Research Actually Shows
Human: 6 studies, 4 groups · Animal: 5 studies, 5 groups · In Vitro: 3
EDUCATIONAL NOTICE: Peptidings exists to make peptide research accessible and honest — not to tell you what to take. The information on this site is for educational and research purposes only. It is not medical advice, and no material here is intended to diagnose, treat, cure, or prevent any disease or health condition. Consult a qualified healthcare provider before making any decisions about peptide use.
GHK-Cu: The Copper Peptide Your Body Already Makes — and Why Rubbing It On Your Skin and Injecting It Are Two Very Different Evidence Stories
BLUF: Bottom Line Up Front
GHK-Cu is a tiny molecule made of just three amino acids and a copper atom. Your body produces it naturally, and its levels drop as you age. When applied to the skin as a cream, it has real clinical evidence: human trials show it reduces wrinkles, thickens skin, and boosts collagen better than vitamin C or retinol. When injected — which is how most biohackers use it — there is zero published human data. That gap between what’s proven on skin and what’s assumed for injection is the most important thing to understand about this compound.
GHK-Cu holds a strange position in the peptide world: it is one of the best-studied skin care ingredients in dermatology and one of the least-studied injectable compounds in biohacking. Same molecule. Same three amino acids. Completely different evidence depending on how you use it.
The compound was discovered in 1973 by Loren Pickart, who noticed that blood plasma from young people could make liver cells from older people behave like younger tissue. The active ingredient turned out to be a tiny peptide — glycine, histidine, and lysine — attached to a copper atom. Later research showed that GHK-Cu levels in human blood drop from roughly 200 ng/mL at age 20 to about 80 ng/mL by age 60, a decline that tracks with slower wound healing, thinner skin, and reduced tissue repair.
After that discovery, two very different paths emerged. The cosmetic industry ran real clinical trials — controlled studies measuring wrinkle depth, skin thickness, and collagen production in human volunteers. The biohacking community adopted GHK-Cu as an injectable peptide and ran no clinical trials at all. This article maps both paths honestly and explains why evidence from rubbing something on your skin does not prove it works when injected.
Table of Contents
Quick Facts: GHK-Cu at a Glance
TYPE
Endogenous copper tripeptide / Naturally occurring peptide-metal complex
GENERIC NAME
Copper Tripeptide-1 (INCI) / GHK-Cu
PRIMARY CLASS
Copper-binding tripeptide with gene-modulatory and tissue repair signaling
RESEARCH STATUS
Multiple controlled human trials (topical/cosmetic); three registered clinical trials; zero published human trials (injectable)
ENDOGENOUS ORIGIN
Found in human plasma, saliva, and urine; produced as a breakdown product of collagen and other extracellular matrix proteins; copper-bound form is the bioactive species
MOLECULAR WEIGHT
~403 Da (GHK free peptide); ~467 Da (GHK-Cu complex). One of the smallest bioactive peptides known — just three amino acids plus copper.
PRIMARY MOLECULAR FUNCTION
Copper delivery to cells; gene expression modulation (~31% of human genes per Connectivity Map analysis); collagen and decorin synthesis stimulation; anti-inflammatory and antioxidant signaling
PLASMA LEVELS
~200 ng/mL at age 20; ~80 ng/mL by age 60 (60% decline)
CLINICAL PROGRAMS
NCT05239615 (topical for photoaging, Phase II, completed 2024); NCT04892136 (hair growth, Phase I/II, terminated 2023); NCT02898454 (androgenetic alopecia, completed 2019)
ROUTE (EVIDENCE-BASED)
Topical only. All published human efficacy data is from topical application (creams, serums, post-procedure gels). No published human trial has tested subcutaneous or intramuscular injection.
EVIDENCE TIER
HALF-LIFE
Not established for injectable route. Topical residence time depends on formulation. As a small tripeptide (~403 Da), GHK-Cu is susceptible to rapid proteolytic degradation in plasma.
STORAGE
Lyophilized powder: –20°C long-term, 2–8°C short-term. Reconstituted: 2–8°C, use within 21–28 days. Protect from light.
FDA STATUS
Not approved as a drug. Widely used as a cosmetic ingredient (Copper Tripeptide-1 INCI). Was placed on FDA Category 2 list (compounding restricted) in late 2023. Expected to return to Category 1 per February 2026 HHS announcement.
WADA STATUS
Not prohibited. GHK-Cu does not appear on the WADA Prohibited List. Athletes may use it without anti-doping consequences.
LEGAL STATUS
Legal to purchase as a cosmetic ingredient and research chemical. Injectable compounding was restricted under Category 2 but may be restored. Topical products widely available over the counter.
COMMUNITY INTEREST
High. GHK-Cu is one of the most-discussed tissue repair peptides in biohacking communities, primarily for injectable use — a route with zero published human data.
VERDICT
The research moves fast. We read all of it so you don’t have to.
New compound reviews, evidence updates, and protocol analysis — sourced, cited, and written for people who actually read the studies.
Subscribe to Peptidings WeeklyWhat Is GHK-Cu?
GHK-Cu is a tripeptide — three amino acids (glycine, histidine, lysine) — with a high-affinity binding site for copper(II) ions. It is one of the smallest biologically active peptides known, weighing roughly 403 daltons without copper and 467 daltons with it. For comparison, BPC-157 has 15 amino acids and thymosin beta-4 has 43. GHK-Cu is molecular minimalism — a fragment so small it barely qualifies as a peptide, yet it modulates the expression of thousands of human genes.
The compound was first isolated from human blood plasma in 1973 by biochemist Loren Pickart at the University of California, San Francisco. Pickart’s observation was elegant: when plasma from 20-year-olds was incubated with liver cells from 60-year-olds, the old cells began producing proteins characteristic of younger tissue. The active factor responsible for this rejuvenation signal was a copper-bound tripeptide that Pickart identified as glycyl-L-histidyl-L-lysine.
GHK-Cu is endogenous — your body makes it. It appears in plasma, saliva, and urine as a natural breakdown product of collagen and other extracellular matrix proteins. When tissue is damaged, local GHK-Cu concentrations rise as the surrounding matrix is degraded, effectively turning structural damage into a chemical repair signal. This is one of the more elegant feedback loops in wound biology: the destruction of old tissue generates a molecule that stimulates the construction of new tissue.
The age-related decline in GHK-Cu is measurable and significant. Plasma concentrations drop from approximately 200 ng/mL at age 20 to 80 ng/mL by age 60 — a 60% reduction. Whether this decline causes age-related healing impairment or merely correlates with it is an open question. The cosmetic and biohacking industries have seized on the former interpretation. The science supports only the latter.
PLAIN ENGLISH
GHK-Cu is a tiny three-amino-acid molecule with a copper atom attached. Your body makes it naturally — it shows up wherever tissue is being broken down and rebuilt. Young people have more of it in their blood than older people. The interesting part is that applying it to skin in a cream has real clinical evidence behind it. Injecting it is a completely different story.
The Route Problem: Why Topical ≠ Injectable
This is the editorial backbone of this article, and it is the distinction that GHK-Cu coverage on every other peptide site fails to make.
What “Topical Evidence” Means
When GHK-Cu is applied to the skin as a cream, serum, or post-procedure gel, it acts locally. It penetrates the epidermis, reaches dermal fibroblasts, stimulates collagen synthesis, and modulates local gene expression. The evidence for this route includes controlled human trials measuring objectively quantifiable endpoints — wrinkle depth, skin thickness, collagen density. The biology is local and the evidence is direct.
What “Injectable Evidence” Means
When GHK-Cu is injected subcutaneously or intramuscularly, it enters systemic circulation. It is now a circulating peptide acting on distant tissues through mechanisms that have been studied only in cell cultures and animal models. No published human study has measured what happens when you inject GHK-Cu. We do not know what systemic concentration is achieved, how long it persists, which tissues it reaches, or what effects it produces in a living human being at injectable doses.
Why the Transfer Doesn’t Work
Topical delivery targets a specific organ (skin) through a specific pathway (transdermal absorption to local dermal cells). Injectable delivery sends the compound everywhere at once. The dose-response relationship is different. The target cell population is different. The safety considerations are different. Copper at cosmetic topical doses is benign. Copper at systemic injectable doses raises legitimate questions about copper homeostasis, hepatic load, and interaction with conditions like Wilson’s disease.
This is not a theoretical concern. It is the reason GHK-Cu is assigned Tier ~ (“It’s Complicated”) rather than a single evidence tier. The topical story and the injectable story are two different stories about the same molecule.
PLAIN ENGLISH
Putting GHK-Cu on your face is not the same as injecting it into your body. When you rub it on skin, it works locally — and we have human studies showing it works. When you inject it, it goes everywhere — and we have zero human studies showing what that does. Claiming injection works because cream works is like saying a pill works because an eye drop works. Same chemical, different story.
Mechanism of Action
GHK-Cu operates through multiple interconnected pathways, which makes it mechanistically fascinating and editorially challenging — there is no single “this is what it does” explanation.
Copper Delivery and Enzymatic Activation
At its most basic level, GHK-Cu is a copper delivery vehicle. Copper is an essential cofactor for numerous enzymes involved in tissue repair: lysyl oxidase (collagen and elastin crosslinking), superoxide dismutase (antioxidant defense), cytochrome c oxidase (mitochondrial energy production), and tyrosinase (melanin synthesis). By delivering copper directly to cells, GHK-Cu supports the enzymatic machinery of repair.
Gene Expression Modulation
This is the most striking feature of GHK-Cu and the one most commonly cited by proponents. Analysis using the Broad Institute’s Connectivity Map database revealed that GHK-Cu affects the expression of approximately 31% of human genes — either upregulating or downregulating them by more than 50% (PMID: 29986520). The pattern of gene expression changes trends toward younger, healthier phenotypes: upregulation of collagen synthesis genes, DNA repair genes, and antioxidant defense genes; downregulation of inflammatory mediators, fibrosis-promoting genes, and metalloproteinases associated with tissue degradation.
A critical editorial note: “affects 31% of human genes” does not mean “improves 31% of human genes.” The Connectivity Map analysis measures gene expression changes in cell lines treated with GHK-Cu in vitro. Whether the same expression shifts occur in living humans at any given dose and route is an assumption, not a demonstrated fact. The gene expression data is a hypothesis generator, not a clinical endpoint.
Collagen and ECM Synthesis
GHK-Cu directly stimulates collagen synthesis in human dermal fibroblasts at nanomolar concentrations, with stimulation beginning between 10–12 and 10–11 M and maximizing at 10–9 M (PMID: 3169264, FEBS Letters, 1988). It also increases production of decorin, dermatan sulfate, and chondroitin sulfate — key components of the extracellular matrix that provide tissue structure and hydration (PMID: 12270842). Simultaneously, it modulates metalloproteinase activity: it stimulates MMP-2 (which remodels damaged collagen) while upregulating TIMP-1 and TIMP-2 (which prevent excessive degradation). This balanced remodeling — tear down the damaged, build up the new — is the mechanistic basis for the topical anti-aging evidence.
Anti-Inflammatory Signaling
GHK-Cu downregulates pro-inflammatory cytokines including TNF-α and IL-6 while upregulating anti-inflammatory pathways (PMID: 29986521). In post-procedure contexts (laser resurfacing, chemical peels), topical GHK-Cu has been shown to reduce inflammatory markers IL-1β and TNF-α by approximately 30% compared to standard care.
Antioxidant Defense
GHK-Cu upregulates antioxidant enzymes including superoxide dismutase, catalase, and glutathione peroxidase, protecting cells against reactive oxygen species (ROS)-induced damage. This is partly a direct copper effect (copper is a cofactor for SOD) and partly a gene-expression effect (upregulation of antioxidant gene transcription).
PLAIN ENGLISH
GHK-Cu does several things at once. It delivers copper — a metal your repair enzymes need to work. It flips genetic switches that tend to push cells toward younger, healthier behavior. It tells fibroblasts to build more collagen. It calms inflammation. And it boosts the cell’s own antioxidant defenses. The problem is that most of this has been demonstrated in cell cultures and skin creams. Whether injection produces these same effects at distant tissues is an assumption, not a measurement.
Clinical Evidence in Humans
Topical — Cosmetic and Dermatological Trials
This is where the real evidence lives. GHK-Cu has been tested in multiple controlled human studies, all using topical formulations:
Facial photoaging trial (71 women, 12 weeks): A GHK-Cu facial cream applied for 12 weeks to women with mild-to-advanced photoaging increased skin density and thickness, reduced laxity, improved clarity, and reduced fine lines and wrinkle depth compared to placebo. Significant improvements appeared as early as week 1 for laxity and clarity, week 2 for fine lines, and week 4 for wrinkles.
Collagen production comparison (thigh skin, 12 weeks): GHK-Cu cream improved collagen production in 70% of women treated, compared to 50% for vitamin C cream and 40% for retinoic acid cream. This is the study most frequently cited by GHK-Cu proponents — and it is a legitimate, controlled comparison showing superiority over two established topical treatments.
Eye cream trial (41 women, 12 weeks): A GHK-Cu eye cream for photodamaged periorbital skin outperformed both placebo and vitamin K cream.
GHK-Cu + hyaluronic acid synergy (PMID: 37062921): A 2023 study in J Cosmetic Dermatology demonstrated that GHK-Cu combined with hyaluronic acid promoted generation of collagen I, IV, and VII, with synergistic effects on collagen IV production (25.4x increase in cell tests, 2.03x in ex-vivo skin tests).
Post-laser resurfacing (2024): A multicenter study of 0.05% GHK-Cu gel after fractional laser resurfacing showed 25% faster epithelial recovery and reduced erythema within 72 hours compared to standard care, with 30% reduction in IL-1β and TNF-α inflammatory markers.
ClinicalTrials.gov registrations: NCT05239615 (topical for photoaging, Phase II, completed 2024 — no results posted); NCT02898454 (androgenetic alopecia, completed 2019 with preliminary positive signals).
Editorial assessment: The topical evidence for GHK-Cu is genuinely strong for a cosmetic/dermatological peptide. Multiple controlled studies, head-to-head comparisons with established treatments, and measurable endpoints. If GHK-Cu were only a topical compound, it would be a straightforward Tier 3 article. The complication is that most consumer interest centers on a route with no clinical data at all.
Injectable — Human Evidence
There is none.
No published, peer-reviewed study has tested subcutaneous, intramuscular, or intravenous GHK-Cu injection in human subjects for any endpoint. Not for wound healing. Not for systemic anti-aging. Not for musculoskeletal repair. Not for cognitive function. Not for anything.
This is not a matter of the evidence being weak or preliminary. The evidence does not exist.
What the Animal and Cell Culture Data Show
GHK-Cu has been studied in preclinical models for wound healing (accelerated closure in rodents), hair growth (Wnt/β-catenin pathway activation in dermal papilla cells, PMID: 26050778), liver regeneration (hepatocyte proliferation after partial hepatectomy), bone healing (osteoblast stimulation), nerve regeneration (neurite outgrowth and Schwann cell proliferation), and angiogenesis (endothelial tube formation). This is a broad preclinical portfolio — and every item in it uses a route or model that has not been replicated in human subjects.
PLAIN ENGLISH
The topical evidence is real: multiple controlled trials on human skin showing wrinkle reduction, collagen boost, and faster post-procedure healing. The injectable evidence is zero: no published study, no human pharmacokinetic data, no controlled outcomes. Every systemic claim you see online is an extrapolation from cream studies and petri dishes.
Gene Expression: The 31% Claim in Context
The headline finding from Pickart and Margolina’s 2018 Connectivity Map analysis (PMID: 29986520) — that GHK-Cu affects 31.2% of human genes — has become the single most-cited statistic in GHK-Cu marketing. It deserves careful contextualization.
What the study actually showed: Using the Broad Institute’s Connectivity Map database (which catalogs gene expression changes in human cell lines exposed to ~1,300 compounds), the researchers identified that GHK treatment shifted the expression of approximately 31% of genes by more than 50% in either direction. The direction of change — upregulation of repair genes, DNA damage response genes, and antioxidant defense; downregulation of inflammatory and degradation pathways — was consistent with a “younger” expression profile.
What this means: GHK-Cu is a remarkably broad-spectrum gene modulator relative to its size. Three amino acids and a copper atom producing expression changes across nearly a third of the genome is biologically noteworthy.
What this does not mean: It does not mean GHK-Cu “resets” or “reprograms” human biology. The Connectivity Map data comes from cell lines treated in vitro. The concentrations used, the cell types tested, and the exposure conditions do not directly translate to what happens when a human applies a cream or injects a solution. Gene expression change in a petri dish is a hypothesis about what might happen in a body. It is not evidence that it does.
PLAIN ENGLISH
The 31% figure is real, the methodology is legitimate, and the directional pattern is interesting. But if you see this number used to sell injectable GHK-Cu, remember: the gene expression data comes from cells in a dish, the clinical evidence comes from creams on skin, and the injectable evidence doesn’t exist. Three data sources, three contexts, and the one most people are paying for has no human data behind it.
The Cancer Question
GHK-Cu’s relationship with cancer is more nuanced than most peptides in this cluster, and the overall signal is cautiously positive.
The theoretical concern: Any compound that stimulates cell proliferation, angiogenesis, and gene expression modulation raises oncological questions. GHK-Cu does all three.
The available evidence: Unlike Tβ4 (where the cancer picture is genuinely mixed), GHK-Cu has several lines of evidence suggesting anti-cancer activity. Connectivity Map analysis shows that GHK upregulates 54 genes involved in DNA damage response and repair. Pickart and Margolina’s 2018 analysis (PMID: 29986520) noted that the gene expression pattern produced by GHK is the “mirror image” of several cancer-associated gene signatures — meaning GHK pushes expression in the opposite direction from what cancer cells typically exhibit. A 2021 study examining GHK-Cu in breast cancer (MCF7) and prostate cancer (PC3) cell lines found gene expression modulation consistent with growth suppression rather than promotion.
The honest assessment: The cancer data for GHK-Cu is more reassuring than for most tissue repair peptides, but it remains mechanistic and in vitro. No long-term epidemiological study has examined cancer rates in users of topical or injectable GHK-Cu. The standard precaution applies: individuals with active malignancies should avoid exogenous growth-modulating peptides outside of clinical trials.
PLAIN ENGLISH
Most tissue repair peptides raise cancer questions because they promote cell growth. GHK-Cu’s gene expression data actually leans in the anti-cancer direction — it seems to turn on DNA repair genes and turn off cancer-associated patterns. That’s reassuring but not conclusive, because all of this data is from cells in dishes, not from people. If you have active cancer, the standard advice applies: don’t use growth-promoting peptides without medical supervision.
Claims vs. Evidence
| Claim | What the Evidence Actually Shows | Verdict |
|---|---|---|
| Reduces wrinkles and reverses skin aging | Multiple controlled human trials (topical) show significant reductions in wrinkle depth, volume, and skin laxity at 12 weeks. Outperforms vitamin C and retinoic acid for collagen production (70% vs. 50% vs. 40% responders). Facial photoaging trial (71 women) showed improvements from week 1. | Solid topical evidence |
| Increases collagen production | 70% of women showed improved collagen production after 12 weeks of topical GHK-Cu vs. 50% for vitamin C and 40% for retinol. Fibroblast studies confirm direct stimulation of collagen I and III at nanomolar concentrations. | Solid topical evidence |
| Heals wounds faster | Post-laser resurfacing study (2024) showed 25% faster epithelial recovery. Animal wound models show accelerated closure. No human trial has tested GHK-Cu for general wound healing. | Topical post-procedure only |
| Grows hair | Wnt/β-catenin activation in dermal papilla cells (in vitro). NCT02898454 (alopecia trial) showed preliminary positive signals. NCT04892136 (hair growth Phase I/II) was terminated in 2023. Evidence is early and incomplete. | Early / incomplete |
| Affects 31% of human genes | Connectivity Map analysis confirms ~31% of genes are modulated >50% in cell lines. This is in vitro data from treated cell cultures, not from human subjects. Gene modulation ≠ gene “reprogramming.” | In vitro — not validated in vivo |
| Reverses aging at the cellular level | Gene expression shifts toward “younger” profiles in cell culture. Plasma decline from 200→80 ng/mL with age is documented. No human trial has demonstrated systemic anti-aging effects from exogenous GHK-Cu. | Correlational + in vitro |
| Injectable GHK-Cu repairs tissue systemically | Zero published human studies on injectable GHK-Cu for any indication. All systemic claims are extrapolated from topical data or animal models. No human pharmacokinetic data for injectable route. | No human evidence |
| Protects the brain / prevents cognitive decline | Gene expression analysis (PMID: 28212278) shows upregulation of neuroprotective genes in cell cultures. In vitro neurite outgrowth data exists. No human neurological study conducted. | In vitro only |
| Better than retinol for skin | One comparison showed superior collagen production (70% vs. 40% responders). But retinol has decades of RCT data across multiple endpoints. GHK-Cu data is smaller-scale. Apples to slightly different apples. | Limited comparison |
| Regenerates liver and bone tissue | Hepatocyte proliferation demonstrated in animal models. Osteoblast stimulation in cell culture. No human trial for either. | Preclinical only |
| Safe for everyone | Topical safety is excellent — no significant adverse events in any human trial. Injectable safety is unknown — no human injectable trial exists. Copper load is a concern for individuals with Wilson’s disease or copper metabolism disorders. | Topical safe; injectable unknown |
| Anti-cancer properties | Gene expression data suggests anti-cancer patterns. In vitro cancer cell line data is more reassuring than for most tissue repair peptides. No epidemiological or clinical cancer data. | Mechanistic only |
We currently don’t have any vetted partners for this compound. Check back soon.
The Human Evidence Landscape
GHK-Cu's evidence landscape looks nothing like the GLP-1 class. There is no pivotal trial program, no outcomes study, no FDA approval for any indication. What exists instead is a half-century of laboratory characterization by Dr. Loren Pickart, a meaningful body of published work on topical applications, and a narrow but genuine set of clinical findings in specific surgical and wound-healing contexts. Separating what has been studied from what has been assumed is most of the work of reading this compound honestly.
The Pickart Lineage and What It Actually Established
Loren Pickart isolated GHK from human plasma in 1973 and spent the subsequent five decades characterizing the tripeptide's interactions with copper, with fibroblasts, and with gene expression profiles. The 2010 Broad Institute Connectivity Map analysis — the origin of the widely-cited "31.2% gene modulation" figure — showed that GHK-Cu shifts the expression of roughly 31% of human genes in the direction of a younger cellular phenotype in cultured fibroblasts.
What Pickart's body of work establishes: GHK-Cu is a biologically active molecule with characterized effects on fibroblast behavior, collagen synthesis, and copper-dependent enzymatic pathways in vitro. What it does not establish: clinical efficacy in any of the community-promoted indications (skin aging at scale, systemic anti-aging, injury recovery beyond wound healing). The leap from gene expression signatures in cell culture to clinical benefit in living humans is exactly the leap this article is designed not to make.
Topical Evidence: Where It's Strongest
The clinical literature on GHK-Cu is almost entirely topical. Most of it is small, unblinded, and industry-sponsored, but it is not nothing.
Skin aging. Several small trials have compared GHK-Cu creams against placebo or vitamin C formulations and reported improvements in fine lines, skin thickness, and elasticity over 12 to 24 weeks. The best-powered of these are still under 100 participants, rarely blinded, and typically sponsored by the manufacturer of the test cream. The direction of effect is consistent; the magnitude is modest; the methodological rigor is, by contemporary dermatology standards, limited.
Wound healing. This is the strongest topical indication. Small trials in diabetic foot ulcers and chronic leg ulcers have shown accelerated healing with GHK-Cu dressings versus standard care. The findings were strong enough that the compound has been incorporated into several commercial wound-care formulations. Even here, the evidence is pilot-scale; there is no multicenter Phase III dataset.
Hair. Small studies on topical GHK-Cu for hair loss have shown modest follicular effects, typically as part of multi-ingredient formulations where isolating the GHK-Cu contribution is difficult. Standalone efficacy at clinically meaningful scale has not been demonstrated.
Injectable Evidence: Almost None
This is the part the peptide community most often misreads. The subcutaneous injection protocols circulating online — the daily microgram doses, the cycle-based approaches, the site-specific injections near joints or scars — are not supported by any published clinical trial in humans. Not one.
What exists: preclinical animal work suggesting wound-healing benefits of systemic GHK-Cu, in vitro work on copper-dependent cellular processes, and anecdotal community reports from self-experimenters. What does not exist: a single controlled human trial of injected GHK-Cu for any indication. Route-of-administration matters enormously here — a topical effect on fibroblasts in a cream does not translate automatically to a systemic effect via subcutaneous injection, and the pharmacokinetics of systemic GHK-Cu have not been characterized in humans with the rigor that would be required to set rational dosing guidance.
The Cancer Question
Periodically, online discussion raises concern that GHK-Cu may promote tumor growth via its angiogenic and fibroblast-activating effects. The published evidence is limited and points in both directions: some preclinical models show GHK-Cu slowing tumor growth, others are equivocal, and there is no prospective human data. The honest position is that the cancer risk profile of systemic GHK-Cu in humans is uncharacterized. Anyone considering injected use in the context of personal or family cancer history should bring that uncertainty into the conversation with a clinician, not wave it away.
What Would Need to Happen
For GHK-Cu to earn the reputation the community ascribes to it, several things would need to happen that have not happened.
A well-powered, blinded topical trial — 200+ participants, independent sponsorship, standardized outcome measures — would settle the skin aging and wound healing signal sizes for good. The pieces exist; the economic incentive to fund the definitive trial largely does not, because GHK-Cu is unpatentable.
A pharmacokinetic study of injected GHK-Cu in humans — dose-response, plasma half-life, tissue distribution — would transform the community protocols from educated guesswork into something closer to rational. This has not been published.
A prospective safety surveillance program for systemic use, addressing the cancer question in a population with relevant risk factors, would answer the single largest unresolved safety concern. This has not been undertaken.
Until those gaps are filled, GHK-Cu remains a well-characterized molecule with genuinely interesting biology, meaningful evidence for topical use in a narrow set of indications, and a community practice pattern — systemic injection for anti-aging and recovery — that substantially outruns what the clinical literature supports.
Side Effects and Safety Profile
Topical Safety (Evidence-Based)
The topical safety profile for GHK-Cu is excellent. Across multiple controlled human trials spanning 12-week application periods, no significant adverse events have been reported. Mild transient irritation at application sites occurs rarely. GHK-Cu is widely used in commercial skincare products (listed as Copper Tripeptide-1) and has a long safety track record in the cosmetic industry.
Injectable Safety (No Data)
No published human study has evaluated the safety of subcutaneous, intramuscular, or intravenous GHK-Cu injection. The injectable safety profile is unknown.
Theoretical safety considerations for injectable GHK-Cu include:
Copper homeostasis: GHK-Cu delivers copper systemically. The body maintains tight copper homeostasis through ceruloplasmin binding and hepatic processing. Repeated injectable copper peptide administration could theoretically alter copper balance — a particular concern for individuals with Wilson’s disease (copper accumulation disorder) or Menkes disease (copper deficiency disorder). The magnitude of this risk at typical injectable peptide doses is unknown.
Injection site reactions: Anecdotal reports from the biohacking community describe transient redness, stinging, and occasional bruising at injection sites. These are consistent with subcutaneous injection of any peptide and are not GHK-Cu-specific.
Systemic effects: Reported anecdotally: mild fatigue, transient headache, skin flushing. None of these have been documented in controlled studies.
Unknown territory: Long-term injectable use, drug interactions, effects on pregnancy and fertility, and pediatric safety have not been studied.
PLAIN ENGLISH
If you put GHK-Cu cream on your skin, the safety data is reassuring — years of cosmetic use, multiple trials, no concerning signals. If you inject it, you are in uncharted territory. The safety of injectable GHK-Cu in humans has not been studied, period. The two most common reassurances — “it’s natural” and “it’s been used in skincare for decades” — are both true and both irrelevant to the question of injectable safety.
Anti-Doping Status
GHK-Cu is not on the WADA Prohibited List. Athletes may use it — topically or otherwise — without anti-doping consequences. This distinguishes GHK-Cu from every other compound in Cluster B: BPC-157, TB-500, thymosin beta-4, and VIP are all prohibited. GHK-Cu is not.
The likely reason is its classification: GHK-Cu is not a growth factor, not a growth hormone releaser, and not a hormone. It is a small copper-binding tripeptide with indirect effects on tissue repair. WADA’s prohibited categories don’t clearly capture its mechanism.
This does not constitute a safety or efficacy endorsement. WADA prohibition status reflects doping classification, not medical evidence.
Legal and Regulatory Status
United States: GHK-Cu has a split regulatory identity.
As a cosmetic ingredient (Copper Tripeptide-1), it is legal, unregulated, and widely available in over-the-counter skincare products. No prescription needed.
As an injectable compound, GHK-Cu was placed on the FDA’s Category 2 bulk drug substance list in late 2023, restricting compounding pharmacies from preparing it. In February 2026, HHS Secretary RFK Jr. announced that GHK-Cu (along with ~14 other peptides) would be moved back to Category 1, allowing compounding again. As of March 2026, the formal Federal Register notice has not been published — the announcement signals intent, not yet regulatory action.
GHK-Cu is not approved as a drug by the FDA for any indication.
International: GHK-Cu is not approved as a drug by any major regulatory agency. It is available as a cosmetic ingredient internationally and as a research chemical from peptide vendors.
Dosing: Topical Evidence-Based Protocols
CRITICAL DISCLAIMER
The dosing information below is derived from published research (topical) and community protocols (injectable). No regulatory authority has established approved dosing for GHK-Cu in any indication. Injectable dosing has no basis in published human research.
Cosmetic creams/serums: Clinical trials typically used preparations containing GHK-Cu at concentrations between 0.01% and 0.1%, applied once or twice daily for 12 weeks. The 71-woman photoaging trial used a facial cream at these concentrations.
Post-procedure gel: The 2024 post-laser resurfacing study used 0.05% GHK-Cu gel applied to treated skin.
This is the only dosing with human efficacy data.
Dosing: Injectable Community Protocols
COMMUNITY-SOURCED INFORMATION
The injectable dosing information below is drawn from community discussion forums and dose extrapolation from animal studies — not from clinical trials or peer-reviewed research. No injectable dose of GHK-Cu has been tested in a controlled human study. These protocols are speculative. Do not self-administer injectable peptides without physician supervision.
Online communities report subcutaneous injection protocols of 1–4 mg per day, typically cycled in 4–8 week periods. Some protocols describe “loading” phases of higher doses followed by maintenance. These protocols are derived from animal study dose extrapolation and have no basis in controlled human research. No published study has tested any injectable GHK-Cu dose in human subjects.
DOSING NOTICE
The injectable community protocols for GHK-Cu are not derived from human clinical data. They are extrapolated from animal models and cosmetic topical studies — two routes with fundamentally different pharmacokinetics. The margin between “I rubbed a cream on my face and it worked in a clinical trial” and “I injected this peptide because someone online said 2 mg daily” is the entire width of evidence-based medicine.
Peptide Preparation and Storage
GHK-Cu is commercially available as a lyophilized powder (bluish-white due to copper content) and as pre-formulated topical products.
Topical products: Store per manufacturer instructions, typically at room temperature away from direct sunlight. Stable in formulated creams and serums.
Lyophilized powder (for reconstitution): Store at –20°C (–4°F) for long-term storage; 2–8°C (36–46°F) for short-term. Protect from light and moisture.
Reconstituted solution: Reconstitute with bacteriostatic water. Store at 2–8°C (36–46°F) and use within 21–28 days. GHK-Cu’s copper complex can be susceptible to interactions with other metal ions — avoid reconstitution in containers with metal components.
Stability notes: As a tripeptide, GHK-Cu is relatively small and can be susceptible to proteolytic degradation. However, the copper complex provides some stability against enzymatic breakdown. The copper binding can be disrupted by competing chelators or extreme pH.
Related Compounds: Side-by-Side Comparison
GHK-Cu belongs to a family of copper-binding and tissue repair peptides. Understanding how it compares to related compounds helps contextualize its evidence position.
AHK-Cu vs. GHK-Cu: AHK-Cu (Alanine-Histidine-Lysine-Copper) is a synthetic analog with a thinner evidence base. Most AHK-Cu claims are extrapolated from GHK-Cu data — they are not the same molecule and should not be treated as interchangeable. GHK-Cu has published human trials; AHK-Cu does not.
Copper Peptides for Hair: Overlapping territory. GHK-Cu’s hair growth data includes in vitro Wnt pathway activation and one completed clinical trial (NCT02898454). Covered in detail in the Copper Peptides for Hair article.
BPC-157 vs. GHK-Cu: Different mechanisms entirely. BPC-157 upregulates growth factors from a gastric juice fragment. GHK-Cu delivers copper and modulates gene expression. BPC-157 has more animal data for musculoskeletal repair; GHK-Cu has better human data for skin. Neither has robust injectable human evidence.
PRP vs. GHK-Cu (topical): For skin rejuvenation, PRP (platelet-rich plasma) has more clinical trial data and is FDA-cleared for point-of-care use. GHK-Cu topical has smaller-scale but controlled evidence. Different delivery systems, overlapping endpoints.
| Compound | Type | Primary Target | Half-Life | FDA Status | WADA Status | Evidence Tier | Primary Tissue Target | Route | Human Evidence Status | Key Differentiator |
|---|---|---|---|---|---|---|---|---|---|---|
| BPC-157 | Synthetic pentadecapeptide (15 amino acids, derived from gastric protective protein BPC) | VEGF / Nitric oxide (proposed multi-target) | ~2–6 hours | Not FDA-approved | Prohibited — S0 (Non-Approved Substances) | Tier 3 — Pilot / Limited Human Data | Musculoskeletal, tendon, ligament, GI tract, CNS | Subcutaneous injection + Oral (both routes studied) | 3 published human pilot studies (~30 subjects combined); no RCTs | Broadest tissue tropism in cluster. Only injury-repair peptide with both oral and injectable evidence. Most evidence in rodent models |
| TB-500 | Synthetic 4-amino-acid fragment (residues 17–23 of Thymosin Beta-4) | Actin binding (cell migration, angiogenesis) | ~2–3 hours | Not FDA-approved | Prohibited — S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics) | Tier 4 — Preclinical Only | Musculoskeletal (muscle, tendon, ligament), cardiac, neurological | Subcutaneous injection | Zero published human clinical trials; animal models and cell culture only | Smallest fragment studied; synthetic derivative of endogenous Thymosin Beta-4. Actin sequestration may drive cell migration |
| Thymosin Beta-4 | Endogenous 43-amino-acid peptide (ubiquitous actin-sequestering protein) | Actin binding, cell migration, angiogenesis | ~2–4 hours | Not FDA-approved | Prohibited — S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics) | Tier 3 — Pilot / Limited Human Data | Broad: muscle, cardiac, neurological, immune, epithelial | Subcutaneous injection + Topical (cosmetics) | Few human studies; cardiac regeneration in early-stage human data; cosmetic formulations | Full-length parent peptide of TB-500. Endogenous compound; ubiquitous in mammalian tissues. More potent than TB-500 fragment in vitro |
| GHK-Cu | Synthetic tripeptide-copper complex (Gly-His-Lys chelated to Cu2+) | Collagen synthesis, wound healing, TGF-beta modulation | ~2 hours topical; ~4–6 hours systemic (estimated) | Not FDA-approved (topical in cosmetics; injectable investigational) | Prohibited — S0 (injectable as growth factor analog); topical unregulated | Tier 5 — It's Complicated | Dermal (collagen, elastin remodeling); broad systemic effects proposed but unverified | Topical (cosmetics — extensive evidence) vs. Subcutaneous injection (preclinical only) | Topical: 30+ years cosmetic use data; Injectable: zero human trials | Route-dependent evidence: topical skin rejuvenation well-established, but injectable claims extrapolate from fundamentally different delivery |
| AHK-Cu | Synthetic copper tripeptide variant (Ala-His-Lys chelated to Cu2+) | Copper chelation, extracellular matrix remodeling, growth factor signaling | ~2–4 hours (estimated) | Not FDA-approved | Not WADA-listed | Tier 4 — Preclinical Only | Dermal (hair follicle, scalp), cosmetic | Topical (cosmetics) | No human clinical trials; in vitro and cosmetic formulation data only | GHK-Cu structural analog with alanine substitution. Primarily studied for hair growth. Less evidence base than GHK-Cu |
| LL-37 | Human cathelicidin antimicrobial peptide (37 amino acids) | Antimicrobial, wound healing, angiogenesis, vitamin D-regulated immune modulation | ~2–4 hours | Not FDA-approved | Not WADA-listed | Tier 3 — Pilot / Limited Human Data | Skin, mucosal surfaces, immune system | Subcutaneous injection, Topical | Limited human data; antimicrobial efficacy well-characterized in vitro; wound healing in animal models | Endogenous host defense peptide. Dual role: direct antimicrobial activity + immune modulation. Vitamin D pathway regulates expression |
| KPV | Alpha-MSH C-terminal tripeptide (Lys-Pro-Val) | NF-kB inhibition, anti-inflammatory (no melanocortin receptor activation) | ~1–2 hours (estimated) | Not FDA-approved | Not WADA-listed | Tier 4 — Preclinical Only | GI tract (colitis models), skin, immune system | Subcutaneous injection, Oral (investigational) | No published human clinical trials; animal models (colitis, dermatitis) only | Smallest anti-inflammatory peptide in cluster (3 amino acids). NF-kB pathway without melanocortin receptor binding. GI-focused research |
| VIP | Endogenous 28-amino-acid neuropeptide (vasoactive intestinal peptide) | VPAC1/VPAC2 receptor agonism; vasodilation, immunomodulation, bronchodilation | ~1–2 minutes (extremely short) | Not FDA-approved (aviptadil in clinical trials) | Not WADA-listed | Tier 2 — Clinical Trials | Pulmonary, GI tract, immune system, neurological | Subcutaneous injection, IV infusion, Intranasal | Multiple Phase 2 trials (ARDS, pulmonary hypertension, sarcoidosis); aviptadil in FDA pipeline | Shortest half-life in cluster. CIRS protocol use. Aviptadil (synthetic VIP) is furthest along FDA pathway among non-approved compounds here |
| KGF / Palifermin | Recombinant keratinocyte growth factor (FGF-7) | FGFR2b receptor; keratinocyte proliferation, epithelial barrier repair | ~3–5 hours | FDA-approved (Kepivance for oral mucositis) | Not WADA-listed | Tier 1 — Approved Drug | Epithelial surfaces (oral mucosa, GI tract, skin) | Intravenous injection (FDA-approved route) | FDA-approved for chemo-induced oral mucositis; multiple Phase 2/3 trials | Only FDA-approved compound in Cluster B. Specific to epithelial tissues. IV-only approved route limits off-label accessibility |
| Substance P | Endogenous 11-amino-acid tachykinin neuropeptide | NK1 receptor agonism; fibroblast migration, angiogenesis, immune activation | ~1–2 minutes | Not FDA-approved | Not WADA-listed | Tier 3 — Pilot / Limited Human Data | Corneal epithelium, skin, nervous system | Topical (corneal), Subcutaneous injection | Human data primarily in corneal wound healing; limited systemic human studies | Endogenous pain signaling peptide repurposed for tissue repair. Strongest human evidence in corneal healing. Dual role: nociception + repair |
| PRP | Autologous platelet-rich plasma (concentrated growth factor preparation) | PDGF, VEGF, TGF-beta release via platelet degranulation | N/A (not a single molecule) | FDA-cleared devices (not drug-approved) | Prohibited — M1 (Manipulation of Blood and Blood Components) | Tier 2 — Clinical Trials | Musculoskeletal (tendon, cartilage, bone), dermal, hair | Injection (local to injury site) | Hundreds of RCTs across orthopedic, dermatologic, and dental applications | Non-peptide. Autologous preparation — no synthetic manufacturing. Largest clinical evidence base in cluster but high study heterogeneity |
| ARA-290 | Synthetic 11-amino-acid peptide (cibinetide; EPO-derived tissue-protective peptide) | Innate Repair Receptor (EPOR/CD131 heterodimer) selective agonist | ~2–4 hours | Not FDA-approved (Phase 2b completed) | Not WADA-listed | Tier 2 — Clinical Trials | Peripheral nerves, retina, cardiac, immune system | Subcutaneous injection (1–8 mg daily in trials); IV infusion (early trials) | Phase 2b complete (sarcoidosis SFN — DOSARA trial); Phase 2 (diabetic neuropathy, diabetic macular edema) | EPO-derived but does NOT bind classical EPO receptor. No erythropoietic activity. Tissue protection without blood doping risk. Furthest clinical development for neuropathy |
Combination Protocols and the “Stacking” Question
COMMUNITY-SOURCED INFORMATION
The combination scenarios described below are drawn from community discussion forums and theoretical pharmacology — not from clinical trials or peer-reviewed research. No combination of GHK-Cu with any other agent has been tested in a controlled study. These considerations are speculative. Do not combine medications without physician supervision.
GHK-Cu is commonly discussed in combination with BPC-157 and/or TB-500 in biohacking communities. No published study has tested GHK-Cu in combination with any other peptide in any model. The theoretical rationale — that copper-mediated gene modulation might complement growth factor upregulation (BPC-157) or actin-mediated cell migration (TB-500) — is mechanistically plausible but entirely unvalidated.
An additional consideration specific to GHK-Cu combinations: mixing copper peptides with other injectable compounds in the same syringe raises compatibility questions. Copper ions can interact with other peptide sequences, potentially degrading either compound or altering bioactivity. There is no published data on the chemical stability of GHK-Cu mixed with BPC-157 or TB-500 in solution.
Frequently Asked Questions
What is GHK-Cu?
GHK-Cu is a tiny molecule made of just three amino acids and a copper atom. Your body produces it naturally — it shows up wherever tissue is being broken down and rebuilt. Young people have about 200 ng/mL in their blood; by age 60, that drops to about 80 ng/mL. It is widely used in skincare products and is also sold as an injectable peptide for research purposes.
Is GHK-Cu FDA-approved?
No. GHK-Cu is not approved as a drug for any condition. It is legal as a cosmetic ingredient (listed as "Copper Tripeptide-1" on skincare labels). As an injectable, it was restricted by the FDA in late 2023. In February 2026, HHS announced plans to allow compounding again, but formal approval of that change is still pending.
Does GHK-Cu actually reduce wrinkles?
Yes — when applied as a cream. Several controlled human trials show that GHK-Cu creams boost collagen production, reduce fine lines, and improve skin firmness. In head-to-head tests, it outperformed both vitamin C and retinoic acid for wrinkle reduction. This is the best-supported use of GHK-Cu and the only one backed by solid human evidence.
Is injecting GHK-Cu supported by evidence?
No. As of March 2026, not a single published study has tested GHK-Cu injection in humans — for wound healing, anti-aging, joint repair, or anything else. This is not a case of weak evidence. The evidence simply does not exist for the injectable route. That doesn't mean it might not work; we just don't have any scientific proof, yet.
Why is GHK-Cu rated "It's Complicated"?
Because the evidence depends entirely on how you use it. Applied to skin, GHK-Cu has multiple human trials behind it. Injected, it has zero human data. Peptidings uses the "It's Complicated" tier when one evidence rating would be misleading. The topical story and the injectable story are two completely different stories about the same molecule.
Does GHK-Cu really affect 31% of human genes?
In lab cells, yes. A 2018 study using the Broad Institute's gene database found that GHK-Cu shifted the activity of about 31% of human genes — turning up repair genes and turning down inflammation genes. That is a striking finding for such a small molecule. But it was measured in cells in a dish, not in a living person. What happens in a petri dish is a clue about what might happen in the body — not proof that it does.
Is GHK-Cu banned in sports?
No. GHK-Cu is not on the WADA Prohibited List, so athletes can use it without anti-doping consequences. This sets it apart from other peptides in its class — BPC-157, TB-500, and thymosin beta-4 are all banned by WADA. GHK-Cu is not.
Can GHK-Cu help with hair loss?
Maybe, but the evidence is thin. Lab studies show GHK-Cu activates a hair-growth pathway in follicle cells. Two clinical trials were registered — one for hair growth (terminated 2023) and one for pattern baldness (completed 2019) — but published results are limited. GHK-Cu may help with hair growth, but we do not yet have strong clinical proof.
Does GHK-Cu cause cancer?
We do not know. GHK-Cu promotes blood vessel growth and cell division — processes that tumors also use. On the other hand, gene studies show it turns up several tumor-suppressing genes. No study has directly tested whether GHK-Cu promotes or prevents cancer in humans. For anyone with an active cancer diagnosis, this unresolved question matters.
How does GHK-Cu compare to BPC-157?
They are very different molecules. GHK-Cu is a three-amino-acid copper peptide with proven skin benefits but no injectable human data. BPC-157 is a 15-amino-acid peptide with over 100 animal studies but only a handful of small, uncontrolled human studies. GHK-Cu's strength is validated topical results. BPC-157's strength is breadth of animal research. Neither has strong human evidence for injection.
Summary of Key Findings
GHK-Cu is a compound that makes the evidence framework work for its money. It is not straightforwardly promising or straightforwardly disappointing. It is a split-screen story where one side has real data and the other has none.
The topical evidence is legitimate. Controlled human trials — not just cell cultures, not just animal models — show that GHK-Cu cream reduces wrinkles, increases collagen production, accelerates post-procedure healing, and outperforms both vitamin C and retinoic acid in direct comparisons. If your interest in GHK-Cu is about skin, the evidence supports careful optimism. This is a compound that works topically in humans, with data to back it up.
The gene expression story is real but out of context. GHK-Cu modulates ~31% of human genes in cell cultures, pushing expression toward younger phenotypes. This is a genuine finding from a legitimate methodology (the Broad Institute’s Connectivity Map). It is also an in vitro finding that has not been validated in living humans at any dose or route. Using it to sell injectable GHK-Cu is a category error.
The injectable evidence does not exist. This is not a weak evidence story or a preliminary evidence story. It is a zero-evidence story. No published human study has tested injectable GHK-Cu for any endpoint. Every systemic claim — tissue repair, neuroprotection, anti-aging, organ regeneration — is extrapolated from topical trials and cell culture experiments. The pharmacokinetics, tissue distribution, effective dose, and safety profile of injectable GHK-Cu in humans are all unknown.
The age-related decline is documented but unproven as therapeutic target. Plasma GHK-Cu drops 60% between ages 20 and 60. This correlates with declining regenerative capacity. Whether replenishing GHK-Cu reverses these declines is an attractive hypothesis with no direct test.
Safety depends on route. Topical safety is excellent — years of cosmetic use, no concerning signals. Injectable safety is unknown. Copper homeostasis is a real consideration for systemic use.
PLAIN ENGLISH
Here’s the honest scorecard. GHK-Cu cream on your face? Real evidence — human trials, measurable results, better than vitamin C and retinol for collagen. GHK-Cu injected into your body? Zero human evidence — not weak evidence, zero. The gene expression data is interesting but it’s from cells in a dish. The age-related decline is real but we don’t know if topping it up helps. If you’re using GHK-Cu for skincare, you’re on solid ground. If you’re injecting it for systemic repair, you’re the clinical trial.
Verdict Recapitulation
GHK-Cu is assigned Tier ~ because no single tier accurately represents its evidence picture. Topical GHK-Cu qualifies as Tier 3 (Pilot / Limited Human Data) — it has controlled human trials demonstrating efficacy for specific dermatological endpoints. Injectable GHK-Cu is Tier 4 (Preclinical Only) — its evidence base consists entirely of cell culture and animal model data, with no human study of any design. The compound earns “Eyes Open” rather than “Reasonable Bet” because the route that most consumers are paying for — injection — has zero human data. For readers considering GHK-Cu: if you’re buying a serum for your face, the evidence supports it. If you’re buying vials for injection, you are operating entirely outside the published evidence base.
Where to Source GHK-Cu
Further Reading and Resources
If you want to go deeper on GHK-Cu, the evidence landscape for tissue repair peptides, or the methodology behind how we evaluate this research, these are the places worth your time.
On Peptidings
- BPC-157 — The most-studied tissue repair peptide in animal models, with a very different mechanism than GHK-Cu.
- TB-500 — A thymosin beta-4 fragment used for tissue repair. WADA-prohibited, unlike GHK-Cu.
- Thymosin Beta-4 — The full-length protein from which TB-500 derives. Mixed cancer data.
- Injury Recovery & Tissue Repair Research Hub — All Cluster B compounds compared.
- Evidence Framework — How Peptidings assigns evidence tiers and verdicts.
External Resources
- PubMed — Biomedical Research Database — Search for “GHK-Cu” or “copper tripeptide.”
- ClinicalTrials.gov — Check for registered or ongoing trials.
- FDA Compounding Bulk Drug Substance List — Current Category 1/2 status.
Selected References and Key Studies
- Pickart L, Margolina A. “Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data.” Int J Mol Sci. 2018;19(7):1987. PubMed
- Pickart L, Margolina A. “GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration.” Brain Sci. 2017;7(2):20. PubMed
- Maquart FX, Pickart L et al. “Stimulation of collagen synthesis in fibroblast cultures by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+.” FEBS Letters. 1988;238(2):343–346. PubMed
- Jiang R et al. “Synergy of GHK-Cu and hyaluronic acid on collagen IV upregulation in human skin.” J Cosmetic Dermatol. 2023;22(6):1836–1842. PubMed
- Pyo HK et al. “GHK-Cu promotes Wnt/β-catenin signaling in human dermal papilla cells.” Organogenesis. 2015. PubMed
- Pickart L. “The Human Tri-Peptide GHK and Tissue Remodeling.” J Biomater Sci Polym Ed. 2008;19(8):969–988. PubMed
- Simeon A et al. “Expression of glycosaminoglycans and small proteoglycans in wounds: modulation by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+.” J Invest Dermatol. 2000;115(6):962–968. PubMed
- Pickart L, Margolina A. “GHK-Cu May Prevent Oxidative Stress in Skin by Regulating Copper and Modifying Expression of Numerous Antioxidant Genes.” Cosmetics. 2018;5(4):58. PubMed
DISCLAIMER
The information presented in this article is for educational and research purposes only. GHK-Cu is not approved by the FDA for any indication in the United States. Nothing in this article constitutes medical advice, and no material here is intended to diagnose, treat, cure, or prevent any disease or health condition. The content is compiled from published research, but the interpretation and application remain uncertain. Adverse events associated with peptide use have been reported. Consult a qualified healthcare provider before making any decisions about peptide use.
The distinction between topical and injectable use is not academic — it reflects a fundamental difference in evidence base, regulatory status, and safety characterization. Users who choose injectable administration are operating outside of any published human evidence.
For the full Peptidings editorial methodology and evidence framework, visit our About page and Evidence Framework pages.
Article last reviewed: April 2, 2026 | Next scheduled review: July 2, 2026
About the Author
Lawrence Winnerman
Founder of Peptidings.com. Former big tech product manager. Independent peptide researcher focused on translating clinical evidence into accessible science.
Next →
Thymosin Beta-4